Duchenne muscular dystrophy (DMD) not only weakens muscles but can also affect the brain, leading to problems with emotions, memory, and learning.

In this study, the authors worked with a mouse model of DMD that shows these brain-related symptoms. They had previously found that a type of drug called an antisense oligonucleotide (ASO) could partially restore the missing brain protein (dystrophin) and improve some of the mice’s emotional and learning difficulties. Here, they tested another strategy using a viral vector (AAV) to deliver similar therapeutic molecules directly into the brain. Although this approach successfully restored some dystrophin in the brain, the results were variable between mice, and overall improvement was less than with ASOs. Importantly, the treated mice did not show behavioral improvements.

These findings highlight both the promise and current limitations of using viral vectors to target brain symptoms in DMD, and they underline the importance of continuing to search for more effective therapies.